106 related articles for article (PubMed ID: 16320268)
1. Analysis of interval-censored longitudinal data with application to onco-haematology.
De Lorenzo P; Henderson R; Valsecchi MG
Stat Med; 2005 Dec; 24(24):3945-57. PubMed ID: 16320268
[TBL] [Abstract][Full Text] [Related]
2. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
3. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
5. Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: application to clinical trial data on chronic lymphocytic leukaemia.
Deslandes E; Chevret S
Stat Med; 2007 Dec; 26(30):5411-21. PubMed ID: 18058850
[TBL] [Abstract][Full Text] [Related]
6. Analysis of left-censored longitudinal data with application to viral load in HIV infection.
Jacqmin-Gadda H; Thiébaut R; Chêne G; Commenges D
Biostatistics; 2000 Dec; 1(4):355-68. PubMed ID: 12933561
[TBL] [Abstract][Full Text] [Related]
7. Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia.
van der Velden VH; Hoogeveen PG; Pieters R; van Dongen JJ
Br J Haematol; 2006 May; 133(4):382-8. PubMed ID: 16643444
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
11. Shared parameter models for the joint analysis of longitudinal data and event times.
Vonesh EF; Greene T; Schluchter MD
Stat Med; 2006 Jan; 25(1):143-63. PubMed ID: 16025541
[TBL] [Abstract][Full Text] [Related]
12. Robustness of a parametric model for informatively censored bivariate longitudinal data under misspecification of its distributional assumptions: A simulation study.
Pantazis N; Touloumi G
Stat Med; 2007 Dec; 26(30):5473-85. PubMed ID: 18058854
[TBL] [Abstract][Full Text] [Related]
13. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
Ruiz-Argüelles GJ; Fernández-Lara D; Estrada-Gómez R; Manzano C; Ruiz-Delgado GJ; Pérez-Romano B; Ruiz-Argüelles A
Lab Hematol; 2007; 13(1):22-6. PubMed ID: 17353179
[TBL] [Abstract][Full Text] [Related]
15. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
Al-Mawali A; Gillis D; Lewis I
Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
DiGiuseppe JA; Fuller SG; Borowitz MJ
Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
[TBL] [Abstract][Full Text] [Related]
18. Nonparametric estimation in a Markov "illness-death" process from interval censored observations with missing intermediate transition status.
Frydman H; Szarek M
Biometrics; 2009 Mar; 65(1):143-51. PubMed ID: 18505421
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
20. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
